the lyla nsouli foundation for children's brain cancer research Company Information
Company Number
07801855
Registered Address
3 burlington gardens, sixth floor, london, W1S 3EP
Industry
Activities of other membership organisations n.e.c.
Telephone
02038679965
Next Accounts Due
September 2025
Group Structure
View All
Shareholders
-0%
the lyla nsouli foundation for children's brain cancer research Estimated Valuation
Pomanda estimates the enterprise value of THE LYLA NSOULI FOUNDATION FOR CHILDREN'S BRAIN CANCER RESEARCH at £3.6k based on a Turnover of £5.9k and 0.6x industry multiple (adjusted for size and gross margin).
the lyla nsouli foundation for children's brain cancer research Estimated Valuation
Pomanda estimates the enterprise value of THE LYLA NSOULI FOUNDATION FOR CHILDREN'S BRAIN CANCER RESEARCH at £0 based on an EBITDA of £-43k and a 4.76x industry multiple (adjusted for size and gross margin).
the lyla nsouli foundation for children's brain cancer research Estimated Valuation
Pomanda estimates the enterprise value of THE LYLA NSOULI FOUNDATION FOR CHILDREN'S BRAIN CANCER RESEARCH at £2.4m based on Net Assets of £738.5k and 3.28x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
The Lyla Nsouli Foundation For Children's Brain Cancer Research Overview
The Lyla Nsouli Foundation For Children's Brain Cancer Research is a live company located in london, W1S 3EP with a Companies House number of 07801855. It operates in the activities of other membership organizations n.e.c. sector, SIC Code 94990. Founded in October 2011, it's largest shareholder is unknown. The Lyla Nsouli Foundation For Children's Brain Cancer Research is a established, micro sized company, Pomanda has estimated its turnover at £5.9k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
The Lyla Nsouli Foundation For Children's Brain Cancer Research Health Check
Pomanda's financial health check has awarded The Lyla Nsouli Foundation For Children'S Brain Cancer Research a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 5 areas for improvement. Company Health Check FAQs
![Health Check Image](/assets/images/big_heart.png)
![positive_score](/assets/images/scoreRate2.png)
2 Strong
![positive_score](/assets/images/scoreRate1.png)
1 Regular
![positive_score](/assets/images/scoreRate0.png)
5 Weak
![size](/assets/images/scoreRate0.png)
Size
annual sales of £5.9k, make it smaller than the average company (£422k)
£5.9k - The Lyla Nsouli Foundation For Children's Brain Cancer Research
£422k - Industry AVG
![growth](/assets/images/scoreRate0.png)
Growth
3 year (CAGR) sales growth of -32%, show it is growing at a slower rate (6.4%)
-32% - The Lyla Nsouli Foundation For Children's Brain Cancer Research
6.4% - Industry AVG
![production](/assets/images/scoreRate1.png)
Production
with a gross margin of 53.9%, this company has a comparable cost of product (53.9%)
53.9% - The Lyla Nsouli Foundation For Children's Brain Cancer Research
53.9% - Industry AVG
![profitability](/assets/images/scoreRate0.png)
Profitability
an operating margin of -723.3% make it less profitable than the average company (1.3%)
-723.3% - The Lyla Nsouli Foundation For Children's Brain Cancer Research
1.3% - Industry AVG
![employees](/assets/images/scoreRate0.png)
Employees
with 1 employees, this is below the industry average (9)
- The Lyla Nsouli Foundation For Children's Brain Cancer Research
9 - Industry AVG
![paystructure](/assets/images/scoreRate-1.png)
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- The Lyla Nsouli Foundation For Children's Brain Cancer Research
- - Industry AVG
![efficiency](/assets/images/scoreRate0.png)
Efficiency
resulting in sales per employee of £5.9k, this is less efficient (£61.7k)
- The Lyla Nsouli Foundation For Children's Brain Cancer Research
£61.7k - Industry AVG
![debtordays](/assets/images/scoreRate-1.png)
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - The Lyla Nsouli Foundation For Children's Brain Cancer Research
- - Industry AVG
![creditordays](/assets/images/scoreRate-1.png)
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - The Lyla Nsouli Foundation For Children's Brain Cancer Research
- - Industry AVG
![stockdays](/assets/images/scoreRate-1.png)
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - The Lyla Nsouli Foundation For Children's Brain Cancer Research
- - Industry AVG
![cashbalance](/assets/images/scoreRate2.png)
Cash Balance
has cash to cover current liabilities for 4390 weeks, this is more cash available to meet short term requirements (223 weeks)
4390 weeks - The Lyla Nsouli Foundation For Children's Brain Cancer Research
223 weeks - Industry AVG
![debtlevel](/assets/images/scoreRate2.png)
Debt Level
it has a ratio of liabilities to total assets of 1.2%, this is a lower level of debt than the average (12%)
1.2% - The Lyla Nsouli Foundation For Children's Brain Cancer Research
12% - Industry AVG
THE LYLA NSOULI FOUNDATION FOR CHILDREN'S BRAIN CANCER RESEARCH financials
![ms excel logo](/assets/images/ms_excel_logo.png)
The Lyla Nsouli Foundation For Children'S Brain Cancer Research's latest turnover from December 2023 is £5.9 thousand and the company has net assets of £738.5 thousand. According to their latest financial statements, we estimate that The Lyla Nsouli Foundation For Children'S Brain Cancer Research has 1 employee and maintains cash reserves of £746.9 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 5,946 | 1,905 | 27,001 | 19,260 | 455,121 | 118,533 | 32,638 | 229,436 | 161,993 | 467,449 | 1,428,427 | 785,796 |
Other Income Or Grants | ||||||||||||
Cost Of Sales | ||||||||||||
Gross Profit | ||||||||||||
Admin Expenses | ||||||||||||
Operating Profit | ||||||||||||
Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pre-Tax Profit | -3,336 | -449,208 | 10,506 | -54,911 | 412,095 | 32,795 | -347,473 | -302,835 | -43,778 | 26,287 | 707,860 | 595,449 |
Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Tax | -3,336 | -449,208 | 10,506 | -54,911 | 412,095 | 32,795 | -347,473 | -302,835 | -43,778 | 26,287 | 707,860 | 595,449 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Profit | -3,336 | -449,208 | 10,506 | -54,911 | 412,095 | 32,795 | -347,473 | -302,835 | -43,778 | 26,287 | 707,860 | 595,449 |
Employee Costs | 0 | 0 | 0 | 0 | 1,524 | 12,818 | 13,247 | 88,966 | 32,747 | 26,033 | 7,847 | 0 |
Number Of Employees | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 0 | 0 | 0 | 0 | 0 | 1,008 | 10,537 | 20,065 | 0 | 1,275 | 4,070 | 3,040 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 1,008 | 10,537 | 20,065 | 0 | 1,275 | 4,070 | 3,040 |
Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10,000 | 0 | 0 | 0 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 449 | 413 | 22,239 | 636 | 492 | 13,144 | 35,658 | 19,160 | 22,897 | 65,828 | 1,680 | 15,593 |
Cash | 746,907 | 840,063 | 1,239,598 | 1,248,816 | 1,337,079 | 964,498 | 898,997 | 1,202,991 | 1,277,013 | 1,419,382 | 1,418,340 | 584,692 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 747,356 | 840,476 | 1,261,837 | 1,249,452 | 1,337,571 | 977,642 | 934,655 | 1,222,151 | 1,309,910 | 1,485,210 | 1,420,020 | 600,285 |
total assets | 747,356 | 840,476 | 1,261,837 | 1,249,452 | 1,337,571 | 978,650 | 945,192 | 1,242,216 | 1,309,910 | 1,486,485 | 1,424,090 | 603,325 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 0 | 173 | 0 | 858 | 1,880 | 0 | 0 | 0 | 0 | 1,123 | 16,907 | 76 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 8,846 | 96,880 | 84,400 | 81,663 | 255,291 | 310,345 | 309,682 | 259,233 | 24,092 | 155,766 | 103,874 | 7,800 |
total current liabilities | 8,846 | 97,053 | 84,400 | 82,521 | 257,171 | 310,345 | 309,682 | 259,233 | 24,092 | 156,889 | 120,781 | 7,876 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total liabilities | 8,846 | 97,053 | 84,400 | 82,521 | 257,171 | 310,345 | 309,682 | 259,233 | 24,092 | 156,889 | 120,781 | 7,876 |
net assets | 738,510 | 743,423 | 1,177,437 | 1,166,931 | 1,080,400 | 668,305 | 635,510 | 982,983 | 1,285,818 | 1,329,596 | 1,303,309 | 595,449 |
total shareholders funds | 738,510 | 743,423 | 1,177,437 | 1,166,931 | 1,080,400 | 668,305 | 635,510 | 982,983 | 1,285,818 | 1,329,596 | 1,303,309 | 595,449 |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||
Operating Profit | ||||||||||||
Depreciation | 0 | 0 | 0 | 0 | 1,008 | 9,529 | 9,528 | 8,521 | 1,275 | 2,795 | 2,795 | 1,520 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors | 36 | -21,826 | 21,603 | 144 | -12,652 | -22,514 | 16,498 | -13,737 | -32,931 | 64,148 | -13,913 | 15,593 |
Creditors | -173 | 173 | -858 | -1,022 | 1,880 | 0 | 0 | 0 | -1,123 | -15,784 | 16,831 | 76 |
Accruals and Deferred Income | -88,034 | 12,480 | 2,737 | -173,628 | -55,054 | 663 | 50,449 | 235,141 | -131,674 | 51,892 | 96,074 | 7,800 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | ||||||||||||
Investing Activities | ||||||||||||
capital expenditure | 0 | 0 | -28,587 | 0 | 0 | |||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | 0 | 0 | -28,587 | 0 | 0 | |||||||
Financing Activities | ||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | ||||||||||||
interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from financing | -1,577 | 15,194 | 0 | 141,442 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash and cash equivalents | ||||||||||||
cash | -93,156 | -399,535 | -9,218 | -88,263 | 372,581 | 65,501 | -303,994 | -74,022 | -142,369 | 1,042 | 833,648 | 584,692 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | -93,156 | -399,535 | -9,218 | -88,263 | 372,581 | 65,501 | -303,994 | -74,022 | -142,369 | 1,042 | 833,648 | 584,692 |
the lyla nsouli foundation for children's brain cancer research Credit Report and Business Information
The Lyla Nsouli Foundation For Children's Brain Cancer Research Competitor Analysis
![competitor_analysis_table_img](/assets/images/competitor_analysis_table.png)
Perform a competitor analysis for the lyla nsouli foundation for children's brain cancer research by selecting its closest rivals, whether from the OTHER SERVICE ACTIVITIES sector, other micro companies, companies in W1S area or any other competitors across 12 key performance metrics.
the lyla nsouli foundation for children's brain cancer research Ownership
THE LYLA NSOULI FOUNDATION FOR CHILDREN'S BRAIN CANCER RESEARCH group structure
The Lyla Nsouli Foundation For Children'S Brain Cancer Research has no subsidiary companies.
Ultimate parent company
THE LYLA NSOULI FOUNDATION FOR CHILDREN'S BRAIN CANCER RESEARCH
07801855
the lyla nsouli foundation for children's brain cancer research directors
The Lyla Nsouli Foundation For Children'S Brain Cancer Research currently has 4 directors. The longest serving directors include Mr Nadim Nsouli (Oct 2011) and Mrs Simone Nsouli (Oct 2011).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Nadim Nsouli | England | 55 years | Oct 2011 | - | Director |
Mrs Simone Nsouli | England | 48 years | Oct 2011 | - | Director |
Mr Walid Fakhry | 56 years | Feb 2012 | - | Director | |
Mr Walid Fakhry | United Kingdom | 56 years | Feb 2012 | - | Director |
P&L
December 2023turnover
5.9k
+212%
operating profit
-43k
0%
gross margin
53.9%
-1.52%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
738.5k
-0.01%
total assets
747.4k
-0.11%
cash
746.9k
-0.11%
net assets
Total assets minus all liabilities
the lyla nsouli foundation for children's brain cancer research company details
company number
07801855
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
94990 - Activities of other membership organisations n.e.c.
incorporation date
October 2011
age
13
incorporated
UK
accounts
Small Company
ultimate parent company
previous names
N/A
last accounts submitted
December 2023
address
3 burlington gardens, sixth floor, london, W1S 3EP
accountant
-
auditor
MHA
the lyla nsouli foundation for children's brain cancer research Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to the lyla nsouli foundation for children's brain cancer research.
![charges](/assets/images/company_charges.png)
the lyla nsouli foundation for children's brain cancer research Companies House Filings - See Documents
date | description | view/download |
---|